CPRX Chief HR Officer receives new stock options and RSU awards

Rhea-AI Filing Summary

Catalyst Pharmaceuticals (CPRX) reported an equity compensation grant to its Chief HR Officer on November 20, 2025. The officer received options to purchase 20,531 shares of common stock at an exercise price of $22.77 per share, along with 6,197 restricted stock units (RSUs). The options vest in three equal annual installments, with one-third vesting on November 20, 2026, one-third on November 20, 2027, and one-third on November 20, 2028. Each RSU represents a right to receive one share of common stock upon vesting, and shares will be delivered to the officer when the RSUs vest. Following these awards, the officer beneficially owns 66,276 options and 72,473 RSUs in total.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Russo Gregg

(Last) (First) (Middle)

355 ALHAMBRA CIRCLE

SUITE 801

(Street)

CORAL GABLES FL 33134

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CATALYST PHARMACEUTICALS, INC. [ CPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief HR Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options to purchase common stock	$22.77	11/20/2025		A		20,531		(1)	11/20/2032	Common Stock	20,531	$0	66,276	D
Restricted Stock Units	(2)	11/20/2025		A		6,197		(1)	(3)	Common Stock	6,197	$0	72,473	D

Explanation of Responses:

1. Derivative securities vest in equal tranches, 1/3rd on November 20, 2026, 1/3rd on November 20, 2027, and 1/3rd on November 20, 2028.

2. Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.

3. Shares of common stock will be delivered to the Reporting Person upon vesting.

	/s/ Gregg Russo	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Catalyst Pharmaceuticals (CPRX) report?

Catalyst Pharmaceuticals reported that its Chief HR Officer received stock options and restricted stock units as part of an equity compensation grant dated November 20, 2025.

How many stock options were granted to the Catalyst Pharmaceuticals (CPRX) officer?

The officer was granted options to purchase 20,531 shares of Catalyst Pharmaceuticals common stock at an exercise price of $22.77 per share.

What restricted stock unit (RSU) award did the Catalyst Pharmaceuticals (CPRX) officer receive?

The Chief HR Officer received 6,197 restricted stock units (RSUs), each representing a right to receive one share of common stock upon vesting.

When do the Catalyst Pharmaceuticals (CPRX) stock options vest?

The derivative securities vest in three equal tranches: 1/3 on November 20, 2026, 1/3 on November 20, 2027, and 1/3 on November 20, 2028.

What does each Catalyst Pharmaceuticals (CPRX) RSU represent?

Each RSU represents a contingent right to receive one share of Catalyst Pharmaceuticals common stock upon vesting, with shares delivered to the officer when the RSUs vest.

How many derivative securities does the Catalyst Pharmaceuticals (CPRX) officer own after this grant?

After the reported transactions, the officer beneficially owns 66,276 options and 72,473 restricted stock units in total.

What is the role of the reporting person at Catalyst Pharmaceuticals (CPRX)?

The reporting person is an officer of Catalyst Pharmaceuticals, serving as the company’s Chief HR Officer.